TEL AVIV, Israel, April 2, 2020 /PRNewswire/ -- Cellect
Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative
technology which enables the functional selection of stem cells,
received an official communication from the China National
Intellectual Property Administration ("CNIPA") regarding its
intention to grant Chinese Patent Application No. 201380021092.5.
Including this latest notification, the Company has 66 patent
applications worldwide, of which 32 are issued/allowed patents.
"China is just the latest
jurisdiction to recognize our innovation as we have sought and
received IP protections globally to help safeguard our inventions,"
commented Dr. Shai Yarkoni, Chief
Executive Officer. "In addition to the clinical trials and
business collaborations that continue to validate our technology,
increasing our IP portfolio is a valuable asset that can be
monetized either internally or externally."
The Company has previously published third-party data
demonstrating improved 'stemness' of stem cells. Specifically, it
significantly improves both proliferation and functional
capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem
cells originating from bone marrow, peripheral blood, umbilical
cord and adipose tissue.
The patent covers a device and a kit adapted for selection of
cells that are resistant to receptor-mediated apoptosis and a
method for using the device and kit. The device enables
simultaneous positive selection for both stem-cells and immune
cells which support engraftment and negative selection for immune
cells which induce graft versus host disease
(GvHD). The device is designed as a closed
compartment cell selection in simplified setting resulting in a
safe, efficacious and affordable solution that currently do not
exist. The present invention further discloses uses for the
device.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a
breakthrough technology, for the selection of stem cells from any
given tissue, that aims to improve a variety of stem cell-based
therapies.
The Company's technology is expected to provide researchers,
clinical community and pharma companies with the tools to rapidly
isolate stem cells in quantity and quality allowing stem cell-based
treatments and procedures in a wide variety of applications in
regenerative medicine. The Company's current clinical trial is
aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company's ability to continue as a going concern; uncertainties of
cash flows and inability to meet working capital needs; the
Company's ability to obtain regulatory approvals; the Company's
ability to obtain favorable pre-clinical and clinical trial
results; the Company's technology may not be validated and its
methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual
Report on Form 20-F for the fiscal year ended December 31, 2018 filed with the U.S. Securities
and Exchange Commission, or SEC, which is available on the SEC's
website, www.sec.gov , and in the Company's periodic filings with
the SEC.
Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
www.cellect.co
+972-9-974-1444
or
EVC Group LLC
Michael Polyviou
+1 (732) 933-2754
mpolyviou@evcgroup.com
View original
content:http://www.prnewswire.com/news-releases/cellect-biotechnology-receives-new-patent-allowance-in-china-301034025.html
SOURCE Cellect Biotechnology Ltd.